Oliver Sartor and Charles Ryan discuss radioligand therapy, differentiating radioisotopes by properties and clinical application. They move to review the PSMA targeted agents and the clinical use of these agents in the treatment of prostate cancer.

Biographies:

A. Oliver Sartor, MD, Professor of Medicine, Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Research, Tulane University

Charles J. Ryan, MD